Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Xếp hạng trong cổ phiếu #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Giá cổ phiếu
$206.50
Vốn hóa thị trường
$365.13B
Thay đổi (1 ngày)
-0.31%
Thay đổi (1 năm)
2.58%
Quốc gia
US
Giao dịch AbbVie Inc. (ABBV)

Danh mục

Lịch sử lợi suất cổ tức của AbbVie Inc. (ABBV)
Lợi suất cổ tức (TTM) của AbbVie Inc. (mã cổ phiếu: ABBV) tại thời điểm 2024-12-31 là: 3.51%
Lợi suất cổ tức trung bình trong 5 năm qua: 3.52%
Lịch sử lợi suất cổ tức của AbbVie Inc. (ABBV) từ 2009 đến 2026
Lợi suất cổ tức vào cuối mỗi năm (TTM)
Năm Lợi suất cổ tức Thay đổi
2026 (TTM) 3.03% 5.57%
2025 2.87% -18.23%
2024 3.51% -8.83%
2023 3.85% 9.69%
2022 3.51% -9.07%
2021 3.86% -10.65%
2020 4.32% -10.93%
2019 4.85% 23.41%
2018 3.93% 47.74%
2017 2.66% -27.32%
2016 3.66% 7.02%
2015 3.42% 34.12%
2014 2.55% -16.12%
2013 3.04% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% 0.00%
2009 0.00% 0.00%
Lợi suất cổ tức (TTM) của các công ty tương tự hoặc đối thủ
Công ty Lợi suất cổ tức Quốc gia
0.63%
US
1.64%
GB
2.15%
US
3.05%
CH
2.84%
US